JP2015524432A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015524432A5 JP2015524432A5 JP2015524242A JP2015524242A JP2015524432A5 JP 2015524432 A5 JP2015524432 A5 JP 2015524432A5 JP 2015524242 A JP2015524242 A JP 2015524242A JP 2015524242 A JP2015524242 A JP 2015524242A JP 2015524432 A5 JP2015524432 A5 JP 2015524432A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- apolipoprotein
- protein
- biologically active
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261675549P | 2012-07-25 | 2012-07-25 | |
| US61/675,549 | 2012-07-25 | ||
| PCT/US2012/066334 WO2014018079A1 (en) | 2012-07-25 | 2012-11-21 | Method of treating hyperglycemic disorders using apoliprotein aiv |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015524432A JP2015524432A (ja) | 2015-08-24 |
| JP2015524432A5 true JP2015524432A5 (enExample) | 2016-01-21 |
| JP6033433B2 JP6033433B2 (ja) | 2016-11-30 |
Family
ID=47295208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015524242A Expired - Fee Related JP6033433B2 (ja) | 2012-07-25 | 2012-11-21 | アポリポタンパク質ａｉｖを用いて高血糖障害を治療する方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10232019B2 (enExample) |
| JP (1) | JP6033433B2 (enExample) |
| AU (1) | AU2012385960B2 (enExample) |
| CA (1) | CA2878684A1 (enExample) |
| WO (1) | WO2014018079A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103391786B (zh) | 2011-01-19 | 2016-06-22 | 辛辛那提大学 | 作为抗糖尿病肽的载脂蛋白a-iv |
| CA2860782A1 (en) | 2012-01-19 | 2013-07-25 | Patrick Tso | Method of treating diabetes using non-glycosylated apolipoprotein a-iv |
| AU2013295721B2 (en) | 2012-07-25 | 2017-07-20 | University Of Cincinnati | Method of treating type I diabetes using apolipoprotein AIV |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| FR2686605B1 (fr) | 1992-01-27 | 1994-03-11 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides, leur preparation et leur utilisation. |
| WO1994027629A1 (en) | 1993-05-28 | 1994-12-08 | Merck & Co., Inc. | Method to control appetite and treat obesity |
| US7105489B2 (en) * | 2002-01-22 | 2006-09-12 | Amylin Pharmaceuticals, Inc. | Methods and compositions for treating polycystic ovary syndrome |
| BR0310100A (pt) | 2002-05-17 | 2007-04-27 | Esperion Therapeutics Inc | métodos para tratar, prevenir ou reduzir a lesão de reperfusão isquêmica em um tecido ou órgão, e para prevenir ou tratar de uma condição associada com a privação de oxigênio, seguida por suprimento de oxigênio aumentado a um tecido ou órgão em necessidade disto |
| US20100267052A1 (en) | 2006-09-01 | 2010-10-21 | American Type Culture Collection | Compositions and methods for diagnosis and treatment of type 2 diabetes |
| AU2009226246A1 (en) | 2008-03-21 | 2009-09-24 | Podiceps B.V. | Diagnostic of pre-symptomatic metabolic syndrome |
| CN103788043B (zh) | 2008-11-28 | 2016-02-03 | 中国医学科学院药物研究所 | 硝克柳胺化合物晶iv型、其制法和其药物组合物与用途 |
| CN103391786B (zh) | 2011-01-19 | 2016-06-22 | 辛辛那提大学 | 作为抗糖尿病肽的载脂蛋白a-iv |
| CA2860782A1 (en) | 2012-01-19 | 2013-07-25 | Patrick Tso | Method of treating diabetes using non-glycosylated apolipoprotein a-iv |
| US9610324B2 (en) * | 2012-07-11 | 2017-04-04 | Esperion Therapeutics, Inc. | Apolipoprotein mixtures |
| AU2013295721B2 (en) | 2012-07-25 | 2017-07-20 | University Of Cincinnati | Method of treating type I diabetes using apolipoprotein AIV |
-
2012
- 2012-11-21 US US14/416,541 patent/US10232019B2/en active Active
- 2012-11-21 CA CA2878684A patent/CA2878684A1/en not_active Abandoned
- 2012-11-21 JP JP2015524242A patent/JP6033433B2/ja not_active Expired - Fee Related
- 2012-11-21 AU AU2012385960A patent/AU2012385960B2/en not_active Ceased
- 2012-11-21 WO PCT/US2012/066334 patent/WO2014018079A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cahn et al. | New forms of insulin and insulin therapies for the treatment of type 2 diabetes | |
| JP2014526441A5 (enExample) | ||
| JP2010031018A5 (enExample) | ||
| EP2611458B1 (en) | Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2 | |
| EP2976096B1 (en) | Insulin dosing regimen | |
| US7485620B2 (en) | Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof | |
| US20080213288A1 (en) | Combined Use Of A Modulator Of CD3 And A GLP-1 Compound | |
| JP2014501762A5 (enExample) | ||
| RU2013133803A (ru) | Способы лечения метаболических нарушений и ожирения при помощи пептидов на основе глюкагона, активных по отношению к рецепторам гип и гпп | |
| JP2020062028A5 (enExample) | ||
| US20130338071A1 (en) | GLP-1 Agonist and Cardiovascular Complications | |
| JP2012529294A5 (enExample) | ||
| JP2018504111A (ja) | ＧＬＰ及び免疫グロブリンハイブリッドＦｃ融合ポリペプチド及びその用途 | |
| JP2017501381A5 (enExample) | ||
| JP2010539950A5 (enExample) | ||
| JP2016512205A5 (enExample) | ||
| JP2010514694A5 (enExample) | ||
| EP3268029B1 (en) | Treatment of type 2 diabetes mellitus patients | |
| JP2016514132A (ja) | ヒト成長ホルモン類似体を用いた小児成長ホルモン分泌不全症の治療 | |
| JP2015504073A5 (enExample) | ||
| JP2012509283A5 (enExample) | ||
| JP2020533302A (ja) | 肥満の治療において使用するためのｍｉｃ−１およびｇｌｐ−１ | |
| JP2021075550A (ja) | グルカゴン類似ペプチド−１受容体亢進剤を含む筋減少症治療用薬学組成物 | |
| Garg | New insulin analogues | |
| JP2020502150A5 (enExample) |